Francesco Galimi
Technik-/Wissenschafts-/F&E-Leiter bei ADICET BIO, INC.
Vermögen: 184 260 $ am 30.04.2024
Profil
Francesco Galimi is currently the Chief Medical Officer & Senior Vice President at Adicet Therapeutics, Inc. and Adicet Bio, Inc. He previously worked as the General Manager-Global Program at Amgen, Inc. from 2015 to 2019 and as the Head-Clinical Development at Onyx Pharmaceuticals, Inc. from 2014 to 2015.
He also served as the Chief Medical Officer & Senior Vice President at resTORbio, Inc. Dr. Galimi earned a doctorate degree from the University of Turin.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ADICET BIO INC
0,12% | 24.01.2024 | 101 801 ( 0,12% ) | 184 260 $ | 30.04.2024 |
Aktive Positionen von Francesco Galimi
| Unternehmen | Position | Beginn |
|---|---|---|
| ADICET BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2019 |
Adicet Therapeutics, Inc.
 Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2019 |
Ehemalige bekannte Positionen von Francesco Galimi
| Unternehmen | Position | Ende |
|---|---|---|
| AMGEN INC. | Corporate Officer/Principal | 01.01.2019 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01.01.2015 |
| ADICET BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Francesco Galimi
| University of Turin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ADICET BIO, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Adicet Therapeutics, Inc.
Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
